BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2151108)

  • 1. Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings.
    Forni G; Giovarelli M; Jemma C; Bosco MC; Caretto P; Modesti A; Santoni A; Forni M; Cortesina G; de Stefani A
    Ann Ist Super Sanita; 1990; 26(3-4):397-409. PubMed ID: 2151108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular engineering of the antitumor immune response.
    Pardoll DM; Golumbek P; Levitsky H; Jaffee L
    Bone Marrow Transplant; 1992; 9 Suppl 1():182-6. PubMed ID: 1387016
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.
    Forni G; Giovarelli M; Santoni A; Modesti A; Forni M
    J Immunol; 1987 Jun; 138(11):4033-41. PubMed ID: 2953796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept.
    Sherif A; Hasan MN; Marits P; Karlsson M; Winqvist O; Thörn M
    Eur Urol; 2010 Jul; 58(1):105-11. PubMed ID: 19766386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interleukin-2 and LAK cells in the local immunotherapy of tumors of the head and neck: an experimental model].
    Sacchi M; Johnson JT; Whiteside TL; Cortesina G
    Acta Otorhinolaryngol Ital; 1989; 9(4):391-8. PubMed ID: 2618654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T; Harada M; Yamada A; Tanaka M; Takao Y; Tanaka Y; Mine T; Sakamoto K; Nakashima T; Itoh K
    Clin Cancer Res; 2006 Feb; 12(4):1325-32. PubMed ID: 16489090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
    Tahara H; Lotze MT
    Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
    Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
    Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
    Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
    BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.
    Sumareva R; Ukrainsky G; Kiremidjian-Schumacher L; Roy M; Wishe HI; Steinfeld AD; Cooper JS
    Radiat Oncol Investig; 1999; 7(1):22-9. PubMed ID: 10030620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.
    Bosco M; Giovarelli M; Forni M; Modesti A; Scarpa S; Masuelli L; Forni G
    J Immunol; 1990 Nov; 145(9):3136-43. PubMed ID: 2212677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer.
    Li D; Jiang W; Bishop JS; Ralston R; O'Malley BW
    Clin Cancer Res; 1999 Jun; 5(6):1551-6. PubMed ID: 10389944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.